Atsunobu Takeda1,2, Hisakata Yamada3,4, Eiichi Hasegawa5, Mitsuru Arima5, Shoji Notomi5, Sayaka Myojin5, Takeru Yoshimura5, Toshio Hisatomi5, Hiroshi Enaida6, Ryoji Yanai7, Kazuhiro Kimura7, Tatsuro Ishibashi5, Koh-Hei Sonoda5. 1. Department of Ophthalmology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan. atakeda@med.kyushu-u.ac.jp. 2. Clinical Research Center, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan. atakeda@med.kyushu-u.ac.jp. 3. Division of Host Defense, Research Center for Prevention of Infectious Diseases, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. 4. Clinical Research Center, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan. 5. Department of Ophthalmology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan. 6. Department of Ophthalmology, Faculty of Medicine, Saga University, Saga, Saga, Japan. 7. Department of Ophthalmology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
Abstract
PURPOSE: To investigate the roles of P2X7 receptors (P2RX7) in the pathogenesis of experimental autoimmune uveoretinitis (EAU). STUDY DESIGN: Experimental. METHODS: Either wild-type (P2rx7 +/+ ) or P2rx7-deficient (P2rx7 -∕- ) mice were immunized with interphotoreceptor retinoid-binding protein (IRBP) peptide 1-20. Severity of EAU was evaluated clinically and histopathologically. The induction of IRBP-specific proliferation and cytokines in draining lymph nodes was assessed by enzyme-linked immunosorbent assays (ELISA). The frequency of activation markers was examined by flow cytometry. Furthermore, inhibitory roles of systemic administration of Brilliant Blue G (BBG), an antagonist for P2RX7, in EAU were also assessed in the wild-type mice. RESULTS: The severity of EAU in P2rx7 -∕- mice was reduced as compared with that in P2rx7 +/+ mice, both clinically and histopathologically. IRBP-specific proliferation in P2rx7 -∕- on day 16 was slightly decreased compared to that in P2rx7 +/+ mice. The induction of IRBP-specific interferon (IFN)-γ and interleukin (IL)-17 in P2rx7 -∕- mice on day 16 was lower than that in P2rx7 +/+ mice. The up-regulation of surface expression of activation markers such as CD25, CD44, and CD69 in response to TCR stimulation in P2rx7 -∕- mice was decreased as compared with that in P2rx7 +/+ mice. Furthermore, neutralization of P2RX7 in vivo by BBG suppressed EAU clinically and histopathologically. IRBP-specific IFN-γ and IL-17 induction in BBG-treated mice was significantly lower than that in vehicle-treated mice. CONCLUSION: The results suggest that P2RX7 is a novel preventative therapeutic target for uveitis as it suppresses the effector functions of both Th1 and Th17 cell responses.
PURPOSE: To investigate the roles of P2X7 receptors (P2RX7) in the pathogenesis of experimental autoimmune uveoretinitis (EAU). STUDY DESIGN: Experimental. METHODS: Either wild-type (P2rx7 +/+ ) or P2rx7-deficient (P2rx7 -∕- ) mice were immunized with interphotoreceptor retinoid-binding protein (IRBP) peptide 1-20. Severity of EAU was evaluated clinically and histopathologically. The induction of IRBP-specific proliferation and cytokines in draining lymph nodes was assessed by enzyme-linked immunosorbent assays (ELISA). The frequency of activation markers was examined by flow cytometry. Furthermore, inhibitory roles of systemic administration of Brilliant Blue G (BBG), an antagonist for P2RX7, in EAU were also assessed in the wild-type mice. RESULTS: The severity of EAU in P2rx7 -∕- mice was reduced as compared with that in P2rx7 +/+ mice, both clinically and histopathologically. IRBP-specific proliferation in P2rx7 -∕- on day 16 was slightly decreased compared to that in P2rx7 +/+ mice. The induction of IRBP-specific interferon (IFN)-γ and interleukin (IL)-17 in P2rx7 -∕- mice on day 16 was lower than that in P2rx7 +/+ mice. The up-regulation of surface expression of activation markers such as CD25, CD44, and CD69 in response to TCR stimulation in P2rx7 -∕- mice was decreased as compared with that in P2rx7 +/+ mice. Furthermore, neutralization of P2RX7 in vivo by BBG suppressed EAU clinically and histopathologically. IRBP-specific IFN-γ and IL-17 induction in BBG-treated mice was significantly lower than that in vehicle-treated mice. CONCLUSION: The results suggest that P2RX7 is a novel preventative therapeutic target for uveitis as it suppresses the effector functions of both Th1 and Th17 cell responses.
Authors: William H Loomis; Sachiko Namiki; Rennolds S Ostrom; Paul A Insel; Wolfgang G Junger Journal: J Biol Chem Date: 2002-12-02 Impact factor: 5.157
Authors: F Di Virgilio; P Chiozzi; D Ferrari; S Falzoni; J M Sanz; A Morelli; M Torboli; G Bolognesi; O R Baricordi Journal: Blood Date: 2001-02-01 Impact factor: 22.113
Authors: Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán Journal: Int Ophthalmol Date: 2013-06-01 Impact factor: 2.031
Authors: Donald E Kimbler; Jessica Shields; Nathan Yanasak; John R Vender; Krishnan M Dhandapani Journal: PLoS One Date: 2012-07-17 Impact factor: 3.240